Edwards Lifesciences
The 10-second takeaway
For the quarter ended March 31 (Q1), Edwards Lifesciences beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share grew.
Gross margins grew, operating margins dropped, net margins dropped.
Revenue details
Edwards Lifesciences logged revenue of $459.2 million. The 19 analysts polled by S&P Capital IQ expected to see a top line of $449.5 million on the same basis. GAAP reported sales were 14% higher than the prior-year quarter's $404.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Non-GAAP EPS came in at $0.53. The 23 earnings estimates compiled by S&P Capital IQ averaged $0.48 per share on the same basis. GAAP EPS of $0.55 for Q1 were 3.8% higher than the prior-year quarter's $0.53 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Margin details
For the quarter, gross margin was 72.3%, 120 basis points better than the prior-year quarter. Operating margin was 18.8%, 60 basis points worse than the prior-year quarter. Net margin was 14.2%, 160 basis points worse than the prior-year quarter.
Looking ahead
Next quarter's average estimate for revenue is $486.0 million. On the bottom line, the average EPS estimate is $0.59.
Next year's average estimate for revenue is $1.96 billion. The average EPS estimate is $2.67.
Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 148 members out of 202 rating the stock outperform, and 54 members rating it underperform. Among 69 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 45 give Edwards Lifesciences a green thumbs-up, and 24 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Edwards Lifesciences is outperform, with an average price target of $83.44.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Edwards Lifesciences the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Edwards Lifesciences to My Watchlist.